ABCL AbCellera Biologics Inc.
AbCellera Biologics Inc. (ABCL) is expected to report earnings on November 4, 2026, after the market close. The consensus earnings estimate is a loss of $0.18 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +96.6% since its last earnings release on August 5, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About AbCellera Biologics Inc.
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease.
Sector
Healthcare
Industry
Biotechnology